{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:12:46Z","timestamp":1778839966209,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology , Ministry of Science and Technology","doi-asserted-by":"publisher","award":["BT\/PR1387\/MED\/12\/515\/2011"],"award-info":[{"award-number":["BT\/PR1387\/MED\/12\/515\/2011"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009053","name":"Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","award":["IA\/S\/15\/1\/501842"],"award-info":[{"award-number":["IA\/S\/15\/1\/501842"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009053","name":"Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","award":["IA\/S\/11\/2500267"],"award-info":[{"award-number":["IA\/S\/11\/2500267"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009053","name":"Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","award":["IA\/CPHE\/17\/1\/503351"],"award-info":[{"award-number":["IA\/CPHE\/17\/1\/503351"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clml.2019.08.013","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T19:05:24Z","timestamp":1570215924000},"page":"130-135.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation"],"prefix":"10.1016","volume":"20","author":[{"given":"Aswin Anand","family":"Pai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anup J.","family":"Devasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Carl","family":"Panetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathya","family":"Mani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raveen Stephen","family":"Stallon Illangeswaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezhilpavai","family":"Mohanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaji","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitha M.","family":"Lakshmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouzia N.","family":"Aboobacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Korula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aby","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biju","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonkuzhali","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.08.013_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.08.013_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41409-018-0302-6","article-title":"Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma","volume":"54","author":"Miller","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.08.013_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2040620718761776","article-title":"The evolution of stem-cell transplantation in multiple myeloma","volume":"9","author":"Mahajan","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2019.08.013_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.hemonc.2017.05.005","article-title":"Recent advances in understanding multiple myeloma","volume":"10","author":"Hari","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.clml.2019.08.013_bib5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.08.013_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12288-018-0989-y","article-title":"Clinical outcomes in multiple myeloma post-autologous transplantation\u2014a single centre experience","volume":"35","author":"Kulkarni","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.clml.2019.08.013_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","article-title":"Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy: melphalan pharmacokinetics in multiple myeloma","volume":"69","author":"Nath","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2019.08.013_bib8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.clpt.6100336","article-title":"Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects","volume":"83","author":"K\u00fchne","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2019.08.013_bib9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/0959-8049(92)90506-W","article-title":"Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma","volume":"28","author":"Ploin","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2019.08.013_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.bmt.1702806","article-title":"Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma","volume":"27","author":"Vassal","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.08.013_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/cpt.644","article-title":"Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial","volume":"102","author":"Cho","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2019.08.013_bib12","first-page":"605","article-title":"Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation","volume":"17","author":"Pinguet","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clml.2019.08.013_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bcp.12906","article-title":"High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation: melphalan exposure is associated with survival in myeloma","volume":"82","author":"Nath","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2019.08.013_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-003-0761-2","article-title":"Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies","volume":"53","author":"Mougenot","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2019.08.013_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00263898","article-title":"High dose melphalan in children with advanced malignant disease","volume":"15","author":"Ninane","year":"1985","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2019.08.013_bib16","first-page":"2379","article-title":"Pharmacokinetics of high-dose melphalan in adults: influence of renal function","volume":"14","author":"Kergueris","year":"1994","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clml.2019.08.013_bib17","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bmt.2014.186","article-title":"Not too little, not too much\u2014just right! (Better ways to give high dose melphalan)","volume":"49","author":"Shaw","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.08.013_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00273524","article-title":"High-dose melphalan dosage adjustment: possibility of using a test-dose","volume":"23","author":"Tranchand","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2019.08.013_bib19","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1016\/j.bbmt.2016.12.451","article-title":"Test dose pharmacokinetics to predict melphalan dosing in children undergoing hematopoietic stem cell transplant (HSCT) with organ impairment","volume":"23","author":"Chandra","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.08.013_bib22","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1182\/blood.V126.23.4314.4314","article-title":"Evaluation of pharmacokinetic-based dose predictions of high dose melphalan in patients with myeloma","volume":"126","author":"Trotman","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.08.013_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.13406","article-title":"Acute myeloid leukaemia: challenges and real world data from India","volume":"170","author":"Philip","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.08.013_bib24","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1016\/j.jchromb.2009.07.033","article-title":"Assays for the quantification of melphalan and its hydrolysis products in human plasma by liquid chromatography\u2013tandem mass spectrometry","volume":"877","author":"Mirkou","year":"2009","journal-title":"J\u00a0Chromatogr B"},{"key":"10.1016\/j.clml.2019.08.013_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-017-0581-x","article-title":"Population pharmacokinetics and optimal sampling strategy for model-based precision dosing of melphalan in patients undergoing hematopoietic stem cell transplantation","volume":"57","author":"Mizuno","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clml.2019.08.013_bib26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2125.2004.02319.x","article-title":"Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation","volume":"59","author":"Nath","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2019.08.013_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2019.08.013_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2125.2007.02862.x","article-title":"Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients","volume":"64","author":"Nath","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2019.08.013_bib29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/psp4.12345","article-title":"Pharmacokinetic-pharmacodynamic model of neutropenia in patients with myeloma receiving high-dose melphalan for autologous stem cell transplant","volume":"7","author":"Cho","year":"2018","journal-title":"CPT Pharmacomet Syst Pharmacol"}],"updated-by":[{"DOI":"10.1016\/j.clml.2025.01.015","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000}}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019313837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019313837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:49:19Z","timestamp":1778838559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019313837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2152265019313837"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.08.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}